Single-variant test meta-analysis results for conditional analyses of hemostatic factors fibrinogen, FVII, FVIII, and vWF
| Factor and variant (gene) . | Ancestry . | No. of participants included in analysis* . | P . | |||
|---|---|---|---|---|---|---|
| UNCOND† . | COND1 . | COND2 . | COND3 . | |||
| Fibrinogen | ||||||
| rs201909029 (FGB) | ALL | 46 841 | 1.97E-10 | 1.35E-09 | 2.27E-10 | 3.44E-10 |
| EUR | 40 091 | 2.69E-10 | 1.83E-09 | 3.10E-10 | 4.68E-10 | |
| AFR | 6 750 | 4.25E-01 | 4.24E-01 | 4.21E-01 | 4.25E-01 | |
| rs6054 (FGB) | ALL | 46 841 | 1.00E-41 | 6.72E-39 | 2.67E-42 | |
| EUR | 40 091 | 4.86E-41 | 3.40E-38 | 5.46E-42 | ||
| AFR | 6 750 | 7.66E-02 | 7.25E-02 | 1.97E-01 | ||
| rs145051028 (FGG) | ALL | 46 841 | 2.93E-06 | 2.67E-06 | 2.90E-06 | |
| EUR | 40 091 | NA | NA | NA | NA | |
| AFR | 6 750 | 2.93E-06 | 2.67E-06 | 2.90E-06 | ||
| rs148685782 (FGG) | ALL | 46 841 | 3.24E-144 | 6.52E-137 | 2.49E-143 | |
| EUR | 40 091 | 1.03E-143 | 2.16E-136 | 8.02E-143 | ||
| AFR | 6 750 | 9.46E-02 | 9.52E-02 | 9.43E-02 | ||
| FVII | ||||||
| rs150525536 (F7) | ALL | 20 549 | 8.29E-20 | 1.02E-22 | ||
| EUR | 16 338 | 2.23E-01 | 1.20E-01 | |||
| AFR | 4 211 | 3.45E-20 | 7.56E-23 | |||
| rs121964926 (F7) | ALL | 20 549 | 5.71E-14 | 1.49E-14 | ||
| EUR | 16 338 | 9.25E-01 | 5.80E-01 | |||
| AFR | 4 211 | 1.75E-20 | 1.95E-20 | |||
| rs3093248 (F7) | ALL | 20 549 | 2.54E-06 | 1.35E-07 | ||
| EUR | 16 338 | NA | NA | |||
| AFR | 4 211 | 2.54E-06 | 1.35E-07 | |||
| FVIII | ||||||
| rs7962217 (VWF) | ALL | 25 477 | 6.60E-11 | 1.64E-09 | ||
| EUR | 20 030 | 8.69E-10 | 1.39E-08 | |||
| AFR | 5 447 | 1.18E-02 | 2.35E-02 | |||
| rs41276738 (VWF) | ALL | 25 477 | 1.56E-11 | 9.85E-14 | ||
| EUR | 20 030 | 1.52E-10 | 1.41E-12 | |||
| AFR | 5 447 | 5.96E-03 | 3.47E-03 | |||
| rs141041254 (STAB2) | ALL | 25 477 | 7.37E-09 | 4.11E-09 | ||
| EUR | 20 030 | 4.03E-09 | 2.22E-09 | |||
| AFR | 5 447 | 9.17E-01 | 9.20E-01 | |||
| vWF | ||||||
| rs141041254 (STAB2) | ALL | 22 636 | 6.82E-08 | 3.29E-08 | ||
| EUR | 18 236 | 2.85E-08 | 1.34E-08 | |||
| AFR | 4 400 | 7.46E-01 | 7.49E-01 | |||
| Factor and variant (gene) . | Ancestry . | No. of participants included in analysis* . | P . | |||
|---|---|---|---|---|---|---|
| UNCOND† . | COND1 . | COND2 . | COND3 . | |||
| Fibrinogen | ||||||
| rs201909029 (FGB) | ALL | 46 841 | 1.97E-10 | 1.35E-09 | 2.27E-10 | 3.44E-10 |
| EUR | 40 091 | 2.69E-10 | 1.83E-09 | 3.10E-10 | 4.68E-10 | |
| AFR | 6 750 | 4.25E-01 | 4.24E-01 | 4.21E-01 | 4.25E-01 | |
| rs6054 (FGB) | ALL | 46 841 | 1.00E-41 | 6.72E-39 | 2.67E-42 | |
| EUR | 40 091 | 4.86E-41 | 3.40E-38 | 5.46E-42 | ||
| AFR | 6 750 | 7.66E-02 | 7.25E-02 | 1.97E-01 | ||
| rs145051028 (FGG) | ALL | 46 841 | 2.93E-06 | 2.67E-06 | 2.90E-06 | |
| EUR | 40 091 | NA | NA | NA | NA | |
| AFR | 6 750 | 2.93E-06 | 2.67E-06 | 2.90E-06 | ||
| rs148685782 (FGG) | ALL | 46 841 | 3.24E-144 | 6.52E-137 | 2.49E-143 | |
| EUR | 40 091 | 1.03E-143 | 2.16E-136 | 8.02E-143 | ||
| AFR | 6 750 | 9.46E-02 | 9.52E-02 | 9.43E-02 | ||
| FVII | ||||||
| rs150525536 (F7) | ALL | 20 549 | 8.29E-20 | 1.02E-22 | ||
| EUR | 16 338 | 2.23E-01 | 1.20E-01 | |||
| AFR | 4 211 | 3.45E-20 | 7.56E-23 | |||
| rs121964926 (F7) | ALL | 20 549 | 5.71E-14 | 1.49E-14 | ||
| EUR | 16 338 | 9.25E-01 | 5.80E-01 | |||
| AFR | 4 211 | 1.75E-20 | 1.95E-20 | |||
| rs3093248 (F7) | ALL | 20 549 | 2.54E-06 | 1.35E-07 | ||
| EUR | 16 338 | NA | NA | |||
| AFR | 4 211 | 2.54E-06 | 1.35E-07 | |||
| FVIII | ||||||
| rs7962217 (VWF) | ALL | 25 477 | 6.60E-11 | 1.64E-09 | ||
| EUR | 20 030 | 8.69E-10 | 1.39E-08 | |||
| AFR | 5 447 | 1.18E-02 | 2.35E-02 | |||
| rs41276738 (VWF) | ALL | 25 477 | 1.56E-11 | 9.85E-14 | ||
| EUR | 20 030 | 1.52E-10 | 1.41E-12 | |||
| AFR | 5 447 | 5.96E-03 | 3.47E-03 | |||
| rs141041254 (STAB2) | ALL | 25 477 | 7.37E-09 | 4.11E-09 | ||
| EUR | 20 030 | 4.03E-09 | 2.22E-09 | |||
| AFR | 5 447 | 9.17E-01 | 9.20E-01 | |||
| vWF | ||||||
| rs141041254 (STAB2) | ALL | 22 636 | 6.82E-08 | 3.29E-08 | ||
| EUR | 18 236 | 2.85E-08 | 1.34E-08 | |||
| AFR | 4 400 | 7.46E-01 | 7.49E-01 | |||
SNPs achieving genome-wide significance threshold (ALL, P = 2.57E-07; EUR, 2.88E-07; AFR, 3.30E-07) are shown in bold.
Only EUR and AFR cohorts were asked to run conditional analyses and not all cohorts participated.
UNCOND, unadjusted analyses; a description of conditional (COND) analyses is provided in supplemental Table 3.